Global Point-of-care Cholesterol Monitoring Devices Market Size By Type (Instruments, Testing Kits), By Application (Hospital, Home Care Settings), By Region, And Segment Forecasts, 2023 to 2032

The Global Point-of-care (POC) Cholesterol Monitoring Devices Market was valued at USD 1.9 billion in 2023 and is expected to reach USD 3.4 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. The market is witnessing robust growth driven by the rising prevalence of cardiovascular diseases, increasing awareness about early diagnosis, and the shift toward personalized healthcare. POC cholesterol monitoring devices allow for rapid testing and immediate results, facilitating timely decision-making in both clinical and home settings.

Drivers

Growing Burden of Cardiovascular Diseases

Rising incidences of cardiovascular conditions, often linked to high cholesterol levels, are significantly propelling the demand for fast and accessible diagnostic tools. Early cholesterol detection is vital for preventing heart attacks and strokes.

Rising Demand for Home-based Testing

Consumers are increasingly adopting self-monitoring solutions for cholesterol, encouraged by user-friendly devices, the convenience of at-home testing, and increasing healthcare costs.

Technological Advancements in POC Devices

Innovations in biosensors, Bluetooth connectivity, and data integration with mobile apps are transforming POC devices into powerful tools for real-time monitoring and data sharing with healthcare providers.

Restraints

Limited Accuracy Compared to Laboratory Tests

While POC devices offer convenience, some devices may lack the precision of laboratory-based diagnostics, affecting clinician confidence in critical cases.

Regulatory and Reimbursement Challenges

Stringent regulatory approval processes and inconsistent reimbursement policies across regions may restrict product availability and consumer adoption in certain markets.

Opportunity

Integration with Digital Health Ecosystems

As digital health platforms grow, integrating POC cholesterol monitors with electronic health records and telemedicine portals can create holistic healthcare solutions and drive device adoption.

Emerging Markets Growth Potential

Countries in Asia-Pacific, Latin America, and the Middle East & Africa are rapidly expanding their primary care infrastructure, offering lucrative opportunities for POC device manufacturers.

Market by System Type Insights

The Handheld Devices segment accounted for the largest market share in 2023. Their portability, affordability, and ease of use have made them particularly popular among individual users and community health centers. Meanwhile, Wearable Cholesterol Monitors, though still emerging, are expected to witness the highest growth during the forecast period, driven by advancements in continuous health tracking technologies.

Market by End-use Insights

The Home Care Settings segment dominated the market in 2023, supported by increasing preference for self-care and remote patient monitoring. This segment benefits from the growing elderly population and the proliferation of user-friendly, app-connected devices. The Hospitals & Clinics segment remains significant, driven by the need for rapid diagnostics in emergency and outpatient departments.

Market by Regional Insights

North America led the global point-of-care cholesterol monitoring devices market in 2023 due to high healthcare spending, growing awareness about preventive health, and a strong presence of leading manufacturers. However, Asia-Pacific is projected to register the highest CAGR during the forecast period, fueled by healthcare digitization, a large undiagnosed population, and favorable government initiatives.

Competitive Scenario

Prominent companies in the global market include Abbott Laboratories, Roche Diagnostics, PTS Diagnostics, Bioptik Technology Inc., Acon Laboratories Inc., and Nova Biomedical. These firms are investing in miniaturization, app integration, and geographic expansion.

In 2023, PTS Diagnostics launched a cloud-connected version of its CardioChek device, enhancing remote patient monitoring capabilities.

In 2024, Abbott expanded its cholesterol testing portfolio with a multi-analyte platform, allowing simultaneous glucose and lipid profiling.

Roche Diagnostics collaborated with a digital health startup in 2025 to integrate cholesterol data into a personalized cardiovascular risk prediction app.

Scope of Work – Global Point-of-care Cholesterol Monitoring Devices Market

Report Metric Details

Market Size (2023) USD 1.9 billion

Projected Market Size (2031) USD 3.4 billion

CAGR (2023–2031) 7.5%

Market Segments By System Type, End-use, Region

Growth Drivers Rise in cardiovascular diseases, home testing demand, device innovations

Opportunities Integration with digital health, growth in emerging markets

Key Market Developments

2023: PTS Diagnostics introduced a Bluetooth-enabled handheld cholesterol testing kit optimized for at-home and primary care use.

2024: Roche Diagnostics unveiled a cholesterol management app that syncs with their POC devices, offering personalized health tips and virtual follow-ups.

2025: Abbott Laboratories secured FDA clearance for its wearable cholesterol biosensor designed for continuous health tracking.

FAQs

What is the current market size of the Global Point-of-care Cholesterol Monitoring Devices Market?

The market was valued at USD 1.9 billion in